{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-075151","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-06-17T20:15:28+00:00","discovered_at":"2026-06-17T20:17:00.246158+00:00","generated_at":"2026-06-17T20:20:50.821306+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aprea shareholders approve reverse stock split (1:3–1:8); all director nominees elected","bullets":["All three Class I director nominees (Duey, Peters, Seizinger) elected; each received >5.4M votes for.","Reverse stock split ratio between 1:3 and 1:8 approved (8.0M for, 210K against); board may effect at its discretion.","Ratification of EisnerAmper as independent auditor for FY2026 passed with 8.1M votes for.","Non-binding say-on-pay passed; advisory vote on frequency favored every 1 year (4.3M votes).","Adjournment proposal also approved with 8.1M votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-075151","json":"https://secwatch.observer/filing/0001104659-26-075151.json","markdown":"https://secwatch.observer/filing/0001104659-26-075151.md","text":"https://secwatch.observer/filing/0001104659-26-075151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/0001104659-26-075151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/tm2618205d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:20:50.821306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ad4787db1e5a7cf2ef0ce791a6b4e99d16c39dc","claim":"Aprea Therapeutics, Inc. shareholders approved A proposal to approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. at the 2026-06-16 meeting.","evidence_excerpt":"The Company’s stockholders voted to approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,056,154 191,486 20,811 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/0001104659-26-075151-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"840519cbddcf87e9cdaa5c22dab2bd78ab095a93","claim":"Aprea Therapeutics, Inc. shareholders approved A proposal to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. at the 2026-06-16 meeting.","evidence_excerpt":"The Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 5,777,837 78,853 25,376 2,386,385","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/0001104659-26-075151-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"962c9f21a525d55691b7ee4a6556fc61dbfea5a5","claim":"Aprea Therapeutics, Inc. shareholders approved A proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year. at the 2026-06-16 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,107,969 44,299 116,183 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/0001104659-26-075151-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"9e178fee37ec412639acf36636db8be7bee02e3c","claim":"Aprea Therapeutics, Inc. shareholders approved A proposal to elect three Class I directors of the Company, Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D., each to hold office until the 2029 Annual Meeting of Stockholders or until their respective successors shall have been duly elected and qualified. at the 2026-06-16 meeting.","evidence_excerpt":"The Company’s stockholders elected the following directors to serve as Class I directors until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Marc Duey 5,817,488 64,578 2,386,385 Richard Peters, M.D. 5,824,115 57,951 2,386,385 Bernd R. Seizinger, M.D., Ph.D. 5,495,110 386,956 2,386,385","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/0001104659-26-075151-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"c7e6e63ae6da37f07279a8904f2642517b930eb7","claim":"Aprea Therapeutics, Inc. shareholders approved A proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, and to authorize the Board of Directors of the Company (the “Board”) to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of not at the 2026-06-16 meeting.","evidence_excerpt":"The Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, and authorized the Board to effect a reverse stock split of the Common Stock at a ratio of not less than one-for-three and not more than one-for-eight of the Common Stock (with all fractional shares rounded up to the nearest whole share) (the “Reverse Stock Split”), with the exact ratio to be set within this range by the Board in its sole discretion (without reducing the authorized number of shares of the Common Stock), and with the Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion (“Proposal 3”). The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,038,052 210,751 19,648 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/0001104659-26-075151-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"cc8cbbb5ef13385d57f61c17587e22c1c877a9d3","claim":"Aprea Therapeutics, Inc. shareholders approved A proposal to approve, by non-binding advisory vote, the frequency of future votes on the compensation of the Company’s named executive officers. at the 2026-06-16 meeting.","evidence_excerpt":"The Company’s stockholders voted to approve, by non-binding advisory vote, the frequency of future votes on the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: 1 Year 2 Years 3 Years Votes Abstaining 4,276,181 22,984 1,056,208 526,693","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/0001104659-26-075151-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}